PMID: 8944373Nov 1, 1996Paper

Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group

European Journal of Gastroenterology & Hepatology
C J MulderM Gerretsen

Abstract

To compare the efficacy and safety of lansoprazole 30 mg daily (LAN30) and omeprazole 40 mg daily (OME40) in the treatment of moderate (Savary-Miller grade II) as well as severe reflux oesophagitis (grade III/IVa). A double-blind, randomized, multicentre study, involving 211 patients at 29 Dutch hospitals. Healing was assessed by endoscopy, performed on admission, after 4 weeks and after 8 weeks if the patient was not healed after 4 weeks. Symptom relief was determined by symptom assessments at the same time points. Safety was evaluated by determining the incidence of adverse events. There was no significant difference in intention-to-treat (ITT) healing rates after 4 weeks (LAN30 87.5%, OME40 80.6%; 95% CI (-4.0; +17.8)) and in the ITT overall healing (LAN30 96.1%, OME40 93.1%; 95% CI (-4.2; +10.2)) rates between the LAN30 and the OME40 group. Relief of reflux-related symptoms at 4 weeks as well as 8 weeks did not differ significantly between the treatment groups. No difference in the incidence of adverse events was observed between the groups. Treatment of patients with reflux oesophagitis grade II, III or IVa with LAN30 was as effective as with OME40 with respect to healing as well as symptom relief.

Citations

Mar 10, 2009·Digestive Diseases and Sciences·Thomas O KovacsDavid A Peura
Apr 12, 2000·Alimentary Pharmacology & Therapeutics·L B GersonR Fass
Aug 10, 2000·Alimentary Pharmacology & Therapeutics·C A Stedman, M L Barclay
Feb 22, 2002·Alimentary Pharmacology & Therapeutics·M FrazzoniV Savarino
May 16, 2002·Drugs·James W FrestonE David Ballard
Dec 13, 2005·Drugs·L Rodrigo
Nov 14, 2008·Current Gastroenterology Reports·Jai Moo Shin, George Sachs
Mar 16, 2001·Expert Opinion on Pharmacotherapy·K G TolmanJ C Fang
Mar 31, 2004·Basic & Clinical Pharmacology & Toxicology·Per M Hellström, Sigurd Vitols
Apr 2, 2002·The American Journal of Gastroenterology·Donald O CastellJeffrey G Levine
May 4, 2011·The American Journal of Gastroenterology·Peter J KahrilasNesta Hughes
Feb 19, 1998·The American Journal of Gastroenterology·D L EarnestP A Greski-Rose
Jun 13, 1998·The American Journal of Gastroenterology·P L PeghiniD O Castell
Feb 16, 2005·Alimentary Pharmacology & Therapeutics·M B FennertyM Sostek
Jan 12, 2010·European Journal of Gastroenterology & Hepatology·Mohammad YaghoobiRichard H Hunt
Nov 20, 1998·Journal of Pediatric Gastroenterology and Nutrition·D M Israel, E Hassall
Aug 3, 2018·Pediatrics in Review·Tonya Adamiak, Karen Francolla Plati
Jun 26, 1998·Postgraduate Medical Journal·J M Lee, C A O'Morain
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Paul MoayyediClare Donnellan
Feb 9, 2012·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·P W WeijenborgA J Bredenoord
May 16, 2019·Biomedical Reports·Daisuke AsaokaAkihito Nagahara
May 21, 2003·Alimentary Pharmacology & Therapeutics·R M KlokJ R B J Brouwers
Mar 27, 2003·Alimentary Pharmacology & Therapeutics·M KawamuraUNKNOWN Study Group of GERD
Nov 6, 2004·Alimentary Pharmacology & Therapeutics·J E McGuiganM M Wolfe
Dec 4, 2004·Alimentary Pharmacology & Therapeutics·K Palmer
May 1, 2001·Alimentary Pharmacology & Therapeutics·P O KatzD O Castell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.